Stockreport

Cabaletta Bio Reports Third Quarter 2025 Financial Results and Provides Business Update

Cabaletta Bio, Inc.  (CABA) 
PDF Rese-cel data presented at multiple medical meetings demonstrated potentially transformative, drug-free clinical responses with a favorable safety profile for autoimmune [Read more]